CinCor Pharma, Inc.
CINCDelisted Feb 24, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001868734
CinCor Pharma, Inc. was delisted on Feb 24, 2023; its insiders filed their last Form 4 on Feb 28, 2023; 102 institutions reported holding it in 13F filings for Q4 2022, worth $460.7M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 102
- Q4 2022, +16 vs. previous quarter
- 13F value
- $460.7M
- Reported value at the end of Q4 2022
- Superinvestors holding
- 0
- At the end of Q4 2022
Superinvestors holding CINC, Q4 2022
No superinvestor reported holding CINC at the end of Q4 2022.
Latest insider trades
Open-market purchases and sales by CinCor Pharma, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2023 (view filing)9:15 PM ET | Nov 28, 2022 | 91 daysLate | Healy James and 4 othersDirector, 10% Owner | SSale | −6.00K | $14.32 | −$85.9K | −100.0%0 after | |
| Feb 27, 2023 (view filing) | Jun 10, 2022 | 262 daysLate | Freeman MasonChief Medical Officer | SSale | −6 | $15.21 | −$91.26 | −0.2%2.49K after | |
| Aug 17, 2022 (view filing)8:01 PM ET | Aug 15 | 2 days | Schwab Andrew J. and 7 others10% Owner | PPurchase | +600.0K | $30.00 | +$18.0M | New position487.3K after | 2 lots |
| Aug 17, 2022 (view filing)4:19 PM ET | Aug 15 | 2 days | Sofinnova Partners SAS and 1 other10% Owner | PPurchase | +133.3K | $30.00 | +$4.00M | +3.3%4.22M after | |
| Aug 15, 2022 (view filing)3:46 PM ET | Aug 11 | 4 days | Sofinnova Management X, L.P. and 2 others10% Owner | PPurchase | +500.0K | $30.00 | +$15.0M | +9.0%6.07M after | |
| Aug 15, 2022 (view filing)2:22 PM ET | Aug 11 | 4 days | GAP Coinvestments CDA, L.P. and 4 others10% Owner | PPurchaseCommon Stock, par value $0.00001 per share ("Common Stock") | +83.0K | $30.00 | +$2.49M | +2.0%4.21M after | Duplicate filing |
| Aug 15, 2022 (view filing)2:21 PM ET | Aug 11 | 4 days | General Atlantic, L.P. and 9 others10% Owner | PPurchaseCommon Stock, par value $0.00001 per share ("Common Stock") | +83.0K | $30.00 | +$2.49M | +2.0%4.21M after | |
| Aug 15, 2022 (view filing) | Aug 11 | 4 days | Healy JamesDirector, 10% Owner | PPurchase | +506.0K | $30.00 | +$15.2M | New position6.00K after | 2 lots |
| Jan 13, 2022 (view filing)9:32 PM ET | Jan 11 | 2 days | GAP Coinvestments CDA, L.P. and 4 others10% Owner | PPurchase | +1.70M | $16.00 | +$27.2M | +70.1%4.13M after | Duplicate filing |
| Jan 13, 2022 (view filing)9:32 PM ET | Jan 11 | 2 days | General Atlantic, L.P. and 9 others10% Owner | PPurchase | +1.70M | $16.00 | +$27.2M | +70.1%4.13M after |
Top 10 13F holders, Q4 2022
The largest institutional positions in CinCor Pharma, Inc. at the end of Q4 2022; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Sofinnova Investments, Inc. | 6,073,949 | $74.6M | 4.54% | −6,000−0.1% | Reduced |
| 5AM Venture Management, LLC | 4,937,646 | $60.7M | 16.31% | 00.0% | Unchanged |
| General Atlantic LLC | 4,209,470 | $51.7M | 0.68% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 2,576,325 | $31.7M | 0.91% | −730,324−22.1% | Reduced |
| Adage Capital Partners GP, L.L.C. | 1,994,583 | $24.5M | 0.06% | −1,034,844−34.2% | Reduced |
| OrbiMed Advisors LLC | 1,906,000 | $23.4M | 0.45% | +1,591,798+506.6% | Added |
| BlackRock Inc. | 1,783,419 | $21.9M | 0.00% | +464,413+35.2% | Added |
| Price T Rowe Associates Inc | 1,423,124 | $17.5M | 0.00% | +145,745+11.4% | Added |
| RTW Investments, LP | 1,389,705 | $17.1M | 0.35% | 00.0% | Unchanged |
| Rock Springs Capital Management LP | 1,116,578 | $13.7M | 0.33% | −89,278−7.4% | Reduced |